# FT-106 audit — WWOX neonatal–infantile parkinsonism "mimicking a neurotransmitter disorder"

**Paper:** PMID **42092735** · PMCID **PMC13378201** · DOI [10.1111/jpc.70401](https://doi.org/10.1111/jpc.70401)
**Citation:** Serce Pehlevan O, Gider Yaman G, Gok A, Tekin Orgun L. *WWOX Mutation as a Rare Cause of Neonatal-Infantile Parkinsonism Mimicking a Neurotransmitter Disorder: A Case Report.* J Paediatr Child Health 2026;62(7):1273–1277.
**Identifiers verified this session** via PubMed `convert_article_ids` + `get_article_metadata` (PMID→PMCID→DOI all reconcile; operator's identifiers were correct).
**Source:** According to PubMed / PMC. Full text retrieved through the PubMed MCP route (`get_full_text_article`, PMC open-access subset).

---

## Header

| Field | Value |
|---|---|
| **Declared read depth** | **FULL TEXT READ** — Introduction, Case Presentation, Discussion, Conclusion, funding/ethics/consent blocks, all read end to end. **NOT read:** the three figure panels (MRI ×3 sub-panels, EEG ×2 sub-panels) — no image or PDF tooling in this deployment. Figure callouts and reference markers were stripped by the extractor (the body reads "(Figure)" with the number removed, and all bracket citations return as empty `[]`), so **no reference can be resolved from this text and no figure was inspected**. There is **no table** in this article. |
| **Genre verdict** | **Single case report.** PubMed publication types: `Case Reports; Journal Article`. The body agrees with the metadata in both directions — no cohort, no series, no literature-review table. The abstract is not a structured abstract but a five-bullet **"Key Points"** block. |
| **Patient count** | **n = 1** (one male neonate, followed to age 4 months). |
| **Allele** | homozygous **WWOX c.716T>G, p.(Leu239Arg)** — missense, **SDR-domain axis** (LEGEND's own mapping; see Q5). |
| **CSF neurotransmitter metabolites** | **NOT MEASURED.** |
| **Dopaminergic therapy** | **NONE TRIED.** No L-DOPA, no carbidopa, no dopamine agonist, no 5-HTP anywhere in the article. |

---

## Q1 · What kind of paper is it, and how many patients?

Single case report, n=1. The authors say so themselves, three times:

> "Here, we describe the first case of neonatal–infantile parkinsonism associated with a pathogenicvariant, clinically mimicking a primary monoamine neurotransmitter synthesis defect."

> "A male neonate was born at 38 weeks of gestation via spontaneous vaginal delivery to a 28-year-old gravida 6, para 4 woman…"

> "According to the policies of the ethics committee of Kocaeli University, **single-patient case reports** that do not contain identifiable personal information do not require formal ethics committee approval."

*(Note: the extractor deletes the italicised gene symbol `WWOX` wherever it is set as an italic run, which is why several sentences read "pathogenicvariant", "-related", "deficiency". The missing token is `WWOX` in every instance; quotes are reproduced exactly as extracted.)*

**No metadata/body genre inversion.** Metadata says case report; the body is a case report. This one is honestly labelled.

---

## Q2 · Is the parkinsonism measured or described?

**DESCRIBED. Narrative clinical description only.** There is **no rating scale, no DAT/SPECT scan, no neurophysiological movement recording, no video-documented scoring, no neuropathology**. The evidentiary object is a bedside description by the treating team.

Verbatim, the entirety of the parkinsonian description:

> "The neonate was admitted to the neonatology unit at an external facility due to respiratory distress and abnormal neurological findings on examination (axial hypotonia with peripheral hypertonia, alternating abnormal posturing, and reduced spontaneous limb movements)."

> "Neurological examination revealed axial hypotonia, hypokinesia of the extremities, facial hypomimia, a hypoactive Moro reflex, and cortical fisting of the thumbs."

> "During hospitalization, he exhibited paroxysmal, alternating tone abnormalities lasting from minutes to hours, characterized by fluctuating hypotonia and hypertonia and prolonged periods of hypokinesia. He also experienced episodes of spinal rigidity triggered by tactile or auditory stimuli."

> "On day 14, stereotyped movements, such as tongue thrusting and bicycling of the lower limbs, were observed."

> "At the most recent evaluation (age 4 months), the patient had been seizure-free for 1 month on valproic acid and clobazam; however, his hypokinetic movement disorder and parkinsonian symptoms persisted."

🔴 **What is absent matters as much as what is present.** No **tremor** is reported anywhere. No **oculogyric crisis** is reported in this patient — the paper names oculogyric crises only as a *generic* feature of monoamine deficiency in the Introduction ("clinically manifesting as dystonia, oculogyric crises, and bradykinesia"), not as an observed finding here. The term "bradykinesia" is likewise used only in the general/Discussion register; the patient's own descriptor is "hypokinesia". So the "parkinsonism" label rests on **hypokinesia + facial hypomimia + fluctuating rigidity**, assembled by the authors into a hypokinetic–rigid syndrome, in a neonate in whom axial hypotonia is simultaneously present.

---

## Q3 · Were CSF neurotransmitter metabolites measured?

**NO. This is the single most important finding of this audit, and it runs against the title.**

> "Cerebrospinal fluid (CSF) neurotransmitter analysis was not performed."

> "In our case, CSF neurotransmitter analysis could not be performed due to lack of availability in our center. Therefore, genetic testing was prioritized."

**No HVA, no 5-HIAA, no pterins (neopterin/biopterin), no 3-OMD value exists in this paper.** There is no table holding them, empty or otherwise — the article contains no table at all. This is not an extraction failure on my side; the authors state twice, in plain text, that the test was never done.

What *was* measured metabolically, and was normal:

> "A comprehensive metabolic evaluation, including serum ammonia and creatine phosphokinase levels, blood gas analysis, acylcarnitine profile, plasma and urine amino acids, and urine organic acids, revealed no abnormalities."

> "Auditory brainstem response testing and thyroid function tests were within normal limits."

**Therefore: the mimicry is CLINICAL ONLY, never biochemical.** The paper establishes that a WWOX-DEE neonate *looked* like a neurotransmitter-disorder candidate to an experienced team — "Given the persistence of hypotonia, abnormal movement patterns including alternating hypokinetic–rigid episodes, and seizures, **a neurotransmitter disorder was considered a preliminary diagnosis**" — and nothing more. It does **not** establish that WWOX-DEE produces a neurotransmitter-disorder biochemical profile, because the biochemistry was never obtained.

### 🔴 Abstract-versus-body inversion — one, and it is material

Key Points bullet 2 reads:

> "mutations should be considered in the differential diagnosis of neonatal hypokinetic–rigid syndromes, **particularly when metabolic and neurotransmitter studies are normal**."

In this patient **neurotransmitter studies were not normal — they were not done**. A reader who stops at the Key Points will carry away "WWOX-DEE with normal CSF neurotransmitters", which is not a datum this paper owns. The Discussion compounds the ambiguity with a general, citation-backed assertion that the extractor cannot let me trace:

> "However, metabolic investigations are typically normal indeficiency, highlighting the importance of early genetic testing for accurate diagnosis []."

That sentence is about the literature, not about this child, and its citation is unresolvable in the extracted text. **The clean statement of this paper's evidentiary content is: normal routine metabolic screen, CSF neurotransmitters never sampled.**

### 🔴 Second over-reach, flagged separately

The mechanistic framing is asserted, not measured. The paper has no DAT imaging, no CSF, no post-mortem, no functional assay in this patient:

> "Our findings are consistent with developmental, nondegenerative parkinsonism, characterized by impaired maturation of dopaminergic networks and synaptic dysfunction rather than neuronal loss."

This is an `IPOTESI`-grade interpretation imported from animal/organoid literature, placed adjacent to case data. **Nothing in this case distinguishes a developmental dopaminergic circuitopathy from a non-dopaminergic movement phenotype of a severe DEE, or from the encephalopathy itself.** LEGEND must not absorb it as a mechanism datum — and per the operator's framing, this paper is not a mechanism paper at all.

---

## Q4 · Was any dopaminergic therapy tried?

**NO. No dopaminergic trial exists in this paper — not successful, not failed, not attempted.** The strings L-DOPA / levodopa / carbidopa / dopamine agonist / 5-HTP / pramipexole / bromocriptine appear nowhere in the full text. There is no "trial of levodopa" sentence to quote, positively or negatively.

The therapy actually reported is entirely **antiseizure**:

> "Phenobarbital was initiated with a loading dose followed by maintenance therapy at 5 mg/kg/day, resulting in a marked reduction in seizure-like events."

> "Initially, vigabatrin was added to phenobarbital; however, the patient continued to experience epileptic spasms despite this combination. After valproic acid was introduced, the frequency of spasms decreased, but the spasms did not fully resolve. Following the addition of clobazam, the spasms completely subsided…"

So the operator's second question — *"did anyone try L-DOPA in a WWOX patient, and what happened?"* — **is not answered by this paper.** The parkinsonian features persisted untreated to the end of follow-up:

> "…his hypokinetic movement disorder and parkinsonian symptoms persisted."

🔴 **I make no proposal about dopaminergic therapy.** There is no dose, no duration and no outcome to report because there was no trial. The absence is the finding.

---

## Q5 · Which WWOX allele?

**Homozygous missense, on the SDR-domain axis — the reference genotype's own structural class.**

> "Whole-exome sequencing identified a homozygous WWOX variant,:c.716T>G, resulting in the predicted amino acid substitution p.(Leu239Arg)."

> "Whole-exome sequencing identified a homozygousvariant (:c.716T>G; p.Leu239Arg). Segregation analysis confirmed that both parents were heterozygous carriers of the variant."

> "This variant was classified as likely pathogenic according to the American College of Medical Genetics and Genomics (ACMG) criteria, based on PM2 (absence in population databases), PM3 (detected in trans in carrier parents), and PP3_Moderate (multiple computational tools supporting a deleterious effect on protein function at a moderate level of evidence), with additional support from phenotypic similarity to previously reportedcases [,]. A two-star pathogenic ClinVar entry further supports this classification []. However, PM5 was not applied in accordance with current recommendations."

Consanguinity is denied but community endogamy is stated:

> "Although parental consanguinity was not present, both parents were from the same village."

**Allele class:** missense, **not** splice, **not** null/truncating. Residue 239 sits in the short-chain dehydrogenase/reductase (SDR) domain — **this mapping is LEGEND's, not the paper's; the article never uses the words "SDR domain".** LEGEND's own structural work already holds L239R on the same helix as the reference genotype's Q230P (`discovery_ledger_current.md`: *"L239R | 🟢 sulla elica — Leu sepolta → Arg"*, relSASA 0.000, 3.5 Å from the anchors), with an outstanding **falsifiable prediction that L239R yields absent protein**.

🔴 **This paper does not test that prediction.** No Western blot, no fibroblast work, no transcript measurement, no protein abundance of any kind. The ledger's L239R prediction remains **untested** after this read, and this audit must not be cited as support for it.

### The intra-allelic point that blocks over-reading

> "The samevariant has previously been reported in association with acquired microcephaly and severe epileptic encephalopathy **without prominent parkinsonian features** []. The hypokinetic–rigid manifestations observed in our patient suggest a potential expansion of the phenotypic spectrum associated with this variant."

LEGEND already holds that prior report as **PAPER 013 / PMID 41153369** (Sunnetci-Akkoyunlu 2025 Turkish DEE cohort, *"two siblings with homozygous WWOX p.L239R"*, status `processed`, T1 contextual). **The same homozygous allele, in at least two other children, did not produce parkinsonism.** Therefore **p.L239R is not an allele-level predictor of a parkinsonian presentation**, and this case cannot be converted into a genotype–phenotype rule. Both the present authors and LEGEND's registry say so.

Minor internal inconsistency, recorded without weight: **PM3 is cited as "detected in trans in carrier parents"** for a variant the same paragraph calls homozygous, and the final classification is stated as *likely pathogenic* while a *two-star pathogenic* ClinVar entry is invoked as support. Neither affects the phenotype reading.

---

## Q6 · Seizure/EEG, MRI and developmental data connecting to what LEGEND holds

**Seizures and EEG** — consistent with the WWOX-DEE profile LEGEND already carries (early-onset seizures evolving to epileptic spasms, multifocal discharges, persistently disorganised background):

> "…admitted to the NICU because of poor feeding and focal twitching involving the perioral region."

> "Video-EEG demonstrated isolated, infrequent, low-amplitude, multifocal sharp waves, predominantly in the right hemisphere (Figure)."

> "Following routine immunization 1 month after discharge, the patient developed recurrent flexor spasms, occurring 20–30 times per day. EEG demonstrated multifocal sharp waves."

> "Following the addition of clobazam, the spasms completely subsided, and the EEG showed marked improvement with a significant reduction in epileptiform discharges, **although the background activity remained disorganized**."

⚠️ **Vigabatrin note, relevant to LEGEND's existing BLOCK-3 vigabatrin entry:** in this single patient, vigabatrin added to phenobarbital **failed** to control epileptic spasms, and control was achieved on valproic acid + clobazam. This is **n=1, unblinded, uncontrolled, sequential add-on** — it is an anecdote about one child's course, **not** evidence about drug choice in WWOX-DEE, and I propose no change to any canonical BLOCK-3 content on its basis.

**MRI** — two studies, both described in text only; **I could not inspect the panels**:

> "Diffusion-weighted brain MRI showed a small diffusion-restricted area in the left lateral thalamus with corresponding low apparent diffusion coefficient and mild ventricular dilatation (Figure). These findings were attributed to his birth history."

> "Brain MRI demonstrated nonspecific structural abnormalities, including bilateral frontotemporal atrophy, corpus callosum hypoplasia, and enlargement of the lateral ventricles (Figure)."

> "Ophthalmologic evaluation showed no signs of optic atrophy or additional structural abnormalities."

Frontotemporal atrophy + corpus callosum hypoplasia + ventriculomegaly sit inside the WWOX-DEE imaging spectrum LEGEND already holds. The **thalamic diffusion restriction is attributed by the authors to perinatal events, not to WWOX**, and no follow-up imaging of that focus is reported — it should not be read as a WWOX imaging feature.

**Growth / development:** birth head circumference was **normal** — "The birth weight was 3820 g, and the head circumference was 35 cm (50th–95th percentile)" — so there is **no congenital microcephaly** here, and **no follow-up OFC is reported**, so this paper says nothing about the acquired microcephaly documented for this same allele elsewhere. **No formal developmental assessment, no developmental quotient, no milestone list** is reported; follow-up ends at **age 4 months**. Dysmorphology and non-CNS findings are recorded once:

> "He has slightly dysmorphic features, including a narrow forehead, thin lips, full cheeks, almond-shaped eyes, a slightly elevated palate, a long philtrum, an umbilical hernia, and a sacral Mongolian spot."

> "Echocardiography revealed a secundum atrial septal defect and a small patent ductus arteriosus."

**Confounder the paper itself raises and then leans on:** meconium-stained delivery, 15 s PPV, APGAR 6/8, clavicular fracture, and an acute thalamic diffusion lesion "attributed to his birth history". The authors convert this perinatal history into a speculative modifier —

> "In our patient, perinatal factors such as meconium-stained amniotic fluid and clavicular fracture indicating perinatal stress may have exacerbated glial dysfunction and dopaminergic imbalance in the context ofdeficiency []."

— which is unmeasured speculation, and which **cuts the other way too**: a perinatally stressed neonate with an acute thalamic lesion has an alternative, non-WWOX explanation available for part of the early movement phenotype. The paper does not adjudicate this, and neither can I.

---

## VERDICT

# `NOTABLE BUT SINGLE-CASE`

**Why not `CLINICALLY ACTIONABLE — differential-diagnosis relevance`,** which was the hypothesis on entry: the actionability of this paper depends entirely on its central claim — that WWOX-DEE can mimic a treatable neurotransmitter disorder — and **the one investigation that could have tested that claim was never performed**. The mimicry is a clinical impression formed by one team, in one neonate, and then abandoned in favour of exome sequencing. There is no CSF profile, no DAT imaging, no scale, no dopaminergic trial, no second patient. Worse for generalisation: **the identical homozygous allele, in two previously reported siblings LEGEND already tracks (PMID 41153369), produced no parkinsonism**, so the presentation is not even allele-predictable. The paper's own actionable recommendation reduces to "sequence early", which is already standard practice in neonatal DEE and is not a finding this case establishes.

**Why not `NOT TRANSFERABLE`:** the observation is real, first-in-human by the authors' claim, on an allele **structurally adjacent to the reference genotype's own SDR helix**, and it names a concrete failure mode — a WWOX-DEE infant being routed into a monoamine-disorder workup. That is worth holding as a **hypothesis about differential diagnosis**, and worth watching for a second case. It is not worth promoting to a phenotype-frequency statement, a mechanism claim, or anything therapeutic.

**Weight for LEGEND:** n=1, descriptive, `IPOTESI` grade. Contributes **no** canonical claim, corroborates **no** existing baseline, tests **no** outstanding prediction (including LEGEND's own L239R-protein-absent prediction, which this paper leaves exactly where it was). Its correct home is a watch-list item on the presentation axis, not the mechanism axis.

---

## What a treating team would want to know

> 🔴 **NOT MEDICAL ADVICE. This section is discussion material for a treating clinical team, not a recommendation, and nothing here should change any patient's management. It is a summary of what one published case report does and does not contain. Every point below is a question to put to a clinical team, not an answer from one.**

- **A single reported infant with homozygous WWOX p.L239R presented with hypokinesia, facial hypomimia and fluctuating rigidity that his own treating team initially considered a neurotransmitter disorder.** The routine metabolic screen (ammonia, CPK, blood gas, acylcarnitines, plasma/urine amino acids, urine organic acids) was normal. That is the whole of the observation.
- **CSF neurotransmitter metabolites — HVA, 5-HIAA, pterins, 3-OMD — were never measured in this child**, by the authors' own explicit statement, because the assay was unavailable at their centre. So this report does **not** tell a clinical team what a WWOX-DEE child's CSF neurotransmitter profile looks like, and it does **not** establish that the resemblance extends past the bedside examination.
- **No dopaminergic therapy of any kind was tried** — no L-DOPA, no carbidopa, no dopamine agonist, no 5-HTP. There is no reported response, and no reported failure, to discuss. The child's antiseizure course (phenobarbital, then vigabatrin without benefit, then valproic acid, then clobazam with resolution of spasms) is a single unblinded sequence in one infant and carries no general implication for drug choice. The parkinsonian features were still present at the last assessment, at age 4 months.
- **The same homozygous allele has been reported in other children without parkinsonian features.** A team should treat this as one child's presentation, not as a feature of the genotype — and the perinatal history in this case (meconium-stained delivery, resuscitation, an acute thalamic diffusion lesion attributed by the authors to birth events) offers a competing partial explanation that the report does not resolve.

---

## What could not be obtained

- **The figure panels.** Three MRI sub-panels and two EEG sub-panels exist; this deployment has no PDF or image tooling, so **no scan, tracing or panel was inspected**, and nothing in this audit derives from one. All imaging and EEG content above comes from the authors' narrative text.
- **The reference list.** The PMC extractor returns every bracket citation as empty `[]`, so **no cited source is resolvable** — including the prior report of p.L239R (separately identified from LEGEND's own registry as PMID 41153369), the ClinVar entry, and the claim that metabolic investigations are "typically normal" in WWOX deficiency. None of those citations were followed.
- **Figure numbering**, stripped by the extractor ("(Figure)" throughout).
- **Nothing was lost to a licence wall.** The article came back as full open-access text; `get_copyright_status` was not needed.

**Read-only session.** No canonical file was read for modification and none was edited. No commit candidate was created. This file is the only artefact written.
